Bold warning: new EU drug rules could strip life-saving medicines from patients. Dutch pharmacists warn that forthcoming European legislation may block compounding pharmacies from supplying other pharmacies, with dangerous consequences for those needing critical treatments.
Representatives from three major groups—the Dutch Association of Hospital Pharmacists (NVZA), the Royal Dutch Pharmacists Association (KNMP), and the Network of Specialized Compounding Pharmacies (NGB)—argue that the law will restrict access to medicines produced by compounding pharmacies. These facilities create drugs not available from standard manufacturers, including pediatric formulations, therapies for rare diseases, and medicines used in emergencies when supply chains falter. If the flow of collegial supply is curtailed, patients in emergency rooms, intensive care units, and operating theaters could face life-threatening delays or gaps in treatment.
Key examples of affected medications include crucial treatments such as flucytosine for severe fungal infections and liquid formulations used for pediatric sedation, seizure management, or blood pressure control. NVZA chair Claartje Samson emphasized the immediacy of the risk: without rapid access to these compounds, patients may not receive stabilization needed to prevent deterioration or death.
At present, Dutch rules tolerate collegial supply as a practice, but it lacks explicit authorization under EU law. Health Minister Robbert D. Bruijn is actively negotiating in Brussels to safeguard this practice and ensure patients continue to receive necessary medicines.
Bruijn stated, “We strongly oppose a change that could make collegial supply impossible. The right of a patient to obtain the medication they need must be preserved.”
This issue highlights a broader question: how can regulatory frameworks balance stricter safety and quality controls with the urgent, sometimes life-saving needs of patients who rely on specialty compounding? And what contingencies should healthcare systems put in place to avoid shortages during regulatory transitions?
What are your thoughts on how to reconcile these concerns? Do you believe the proposed EU rules strike the right balance between safety and access, or do they risk harming patients who depend on compounded medicines? Share your perspective in the comments.
